Sector News

Sanofi teams up with Verily to create diabetes JV

September 13, 2016
Life sciences

French drugmaker Sanofi has teamed up with Alphabet’s US-based life sciences company Verily (formerly Google Life Sciences) to launch of a joint-venture – Onduo – with the aim of improving the management of diabetes.

The group say Onduo’s mission is to help people with diabetes live full, healthy lives by developing comprehensive solutions that combine devices, software, medicine, and professional care to enable simple and intelligent disease management.

The JV will leverage Verily’s experience in miniaturised electronics, analytics, and consumer software development, and Sanofi’s clinical expertise and experience in bringing innovative treatments.

“From monitoring food intake to testing glucose levels to actively seeking medical care, the challenges both on the physical and mental well-being of a person living with diabetes are incredibly difficult,” said Dr Riff, chief executive of Onduo.

“We want to develop solutions that allow people living with diabetes to focus on the things they love and enjoy in life by providing tools to make dealing with their diabetes less burdensome.”

The initial focus is on type II diabetes, with the JV striving to develop solutions that could help people “make better decisions about their day to day health, ranging from improved medication management to improved habits and goals”, the groups said. But eventually the focus will extend to the type I diabetes community, and people at risk of developing the condition.

There is still huge unmet medical need in diabetes, given that less than a third of patients with type I and nearly half of all patients with type II forms of the condition are failing to meet their blood sugar targets, placing them at much higher risk of serious complications.

“The integration of multiple interventions, such as data-driven patient support and devices in addition to treatment, can help improve outcomes,” said Peter Guenter, head of Sanofi’s Global Diabetes & Cardiovascular Business Unit.

Onduo will adopt “a more service-centric approach”, which the firms believe “will help societies cope with the burden of this epidemic,” he added.

By Selina McKee

Source: Pharma Times

comments closed

Related News

June 8, 2024

Lilly CFO leaves to join Alphabet

Life sciences

Anat Ashkenazi will leave Eli Lilly’s executive suite at the end of July to become CFO and senior vice president of Google and Alphabet. Ashkenazi has been CFO at Lilly since 2021 and originally joined the company in 2001. Over her 23-year career at the Indianapolis-based drugmaker, Ashkenazi also served as controller, CFO of Lilly Research Laboratories and as the finance chief for several global divisions within the company.

June 8, 2024

Edwards Lifesciences to cell Critical Care to BD

Life sciences

Edwards Lifesciences (NYSE: EW) announced it has entered into a definitive agreement to sell its Critical Care product group to BD (Becton, Dickinson and Company), in an all-cash transaction valued at $4.2 billion. With this agreement, Edwards is no longer pursuing the previously announced spin-off of Critical Care.

June 8, 2024

Danaher names Martin Stumpe as chief data and AI officer

Life sciences

The company, which owns diagnostics and life sciences businesses including Beckman Coulter and Cepheid, said the appointment reflects its increasing investment in AI as “a driving force for innovation and productivity.” Danaher is focused on AI by also spending on its internal capabilities and partnering with academic groups.

How can we help you?

We're easy to reach